Hot Investor Mandate: Western Europe VC’s New Fund Invests Up to $25M in Europe-Based Therapeutics in Oncology, CNS, and Rare Disease

3 Jun

A VC based in Western Europe is currently raising a new fund which will be focused specifically on therapeutics. Around 50% of their new fund will be dedicated to venture building, and the other half will be dedicated to traditional venture investing. The firm will invest in European and Israeli companies, and will invest from lead identification to IND-stage, although the firm is open to investing in clinical-stage companies. The firm will invest between $5-25M per investment (seed, series A, series B).

The firm is looking to invest only in therapeutics. Within therapeutics, the firm is agnostic to modality. The firm is primarily interested in the indications of oncology (particularly glioblastoma, pancreatic cancer and sarcoma), rare diseases and CNS disorders, particularly those with a genetic origin. The firm is interested in First-In-Class and Best-In-Class therapeutics, but may consider repurposed therapeutics for CNS only.

The firm is interested in investing in experienced management teams. The firm prefers to co-invest, and may take a board seat, but does not require it.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: